CareDx, Inc - רווח נקי למניה בארבעת הרבעונים האחרונים CDNA

CareDx, Inc (CDNA) maintains absolute pricing power based on the inelastic demand for AlloSure non-invasive diagnostics. The GURU.Markets service features a chart of the net income per share YoY ttm growth rate, where the 91.50 metric determines the parameter status. Its "gold standard" status in transplantology guarantees physician trust, while its niche leadership is reinforced by deep integration with the largest medical centers.
CDNA (CareDx, Inc): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The scalability of AI analytics in CareDx, Inc (CDNA) genetic tests allows for the reduction of unit costs as the patient base grows, transforming R&D expenditures into operational leverage. This rolling year net income per share trend measures the percentage change in EPS (TTM) relative to the same period, enabling investors to filter out market noise and assess the actual efficiency of intellectual property monetization.